S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.35 (+0.17%)
MSFT   249.20 (+0.13%)
META   138.87 (-1.01%)
GOOGL   101.40 (-0.24%)
AMZN   121.12 (+0.02%)
TSLA   240.70 (-3.50%)
NVDA   131.97 (+0.23%)
NIO   16.09 (-3.83%)
BABA   84.42 (+0.37%)
AMD   67.86 (-0.06%)
T   15.95 (-0.87%)
MU   54.74 (+1.45%)
CGC   3.06 (-2.55%)
F   12.50 (+1.13%)
GE   67.51 (-0.04%)
DIS   100.72 (-0.71%)
AMC   7.34 (-6.26%)
PYPL   94.10 (+1.41%)
PFE   44.11 (-0.79%)
NFLX   237.30 (-1.43%)
S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.35 (+0.17%)
MSFT   249.20 (+0.13%)
META   138.87 (-1.01%)
GOOGL   101.40 (-0.24%)
AMZN   121.12 (+0.02%)
TSLA   240.70 (-3.50%)
NVDA   131.97 (+0.23%)
NIO   16.09 (-3.83%)
BABA   84.42 (+0.37%)
AMD   67.86 (-0.06%)
T   15.95 (-0.87%)
MU   54.74 (+1.45%)
CGC   3.06 (-2.55%)
F   12.50 (+1.13%)
GE   67.51 (-0.04%)
DIS   100.72 (-0.71%)
AMC   7.34 (-6.26%)
PYPL   94.10 (+1.41%)
PFE   44.11 (-0.79%)
NFLX   237.30 (-1.43%)
S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.35 (+0.17%)
MSFT   249.20 (+0.13%)
META   138.87 (-1.01%)
GOOGL   101.40 (-0.24%)
AMZN   121.12 (+0.02%)
TSLA   240.70 (-3.50%)
NVDA   131.97 (+0.23%)
NIO   16.09 (-3.83%)
BABA   84.42 (+0.37%)
AMD   67.86 (-0.06%)
T   15.95 (-0.87%)
MU   54.74 (+1.45%)
CGC   3.06 (-2.55%)
F   12.50 (+1.13%)
GE   67.51 (-0.04%)
DIS   100.72 (-0.71%)
AMC   7.34 (-6.26%)
PYPL   94.10 (+1.41%)
PFE   44.11 (-0.79%)
NFLX   237.30 (-1.43%)
S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.35 (+0.17%)
MSFT   249.20 (+0.13%)
META   138.87 (-1.01%)
GOOGL   101.40 (-0.24%)
AMZN   121.12 (+0.02%)
TSLA   240.70 (-3.50%)
NVDA   131.97 (+0.23%)
NIO   16.09 (-3.83%)
BABA   84.42 (+0.37%)
AMD   67.86 (-0.06%)
T   15.95 (-0.87%)
MU   54.74 (+1.45%)
CGC   3.06 (-2.55%)
F   12.50 (+1.13%)
GE   67.51 (-0.04%)
DIS   100.72 (-0.71%)
AMC   7.34 (-6.26%)
PYPL   94.10 (+1.41%)
PFE   44.11 (-0.79%)
NFLX   237.30 (-1.43%)
NASDAQ:SPPI

Spectrum Pharmaceuticals - SPPI News Today

$0.43
-0.02 (-4.85%)
(As of 10/5/2022 04:31 PM ET)
Add
Compare
Today's Range
$0.42
▼
$0.44
50-Day Range
$0.42
▼
$1.56
52-Week Range
$0.41
▼
$2.45
Volume
2.48 million shs
Average Volume
3.91 million shs
Market Capitalization
$80.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.83
Get Spectrum Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SPPI and its competitors with MarketBeat's FREE daily newsletter.



SPPI Media Mentions By Week

SPPI Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

SPPI
News Sentiment
▼
1.38

0.80
▲
Average
Medical
News Sentiment

SPPI News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

SPPI Articles
This Week
▼
1

1
▲
SPPI Articles
Average Week

SourceHeadline
benzinga.com logoBragar Eagel & Squire, P.C. Is Investigating Cantaloupe, Compass, and Spectrum and Encourages Investors to Contact the Firm
benzinga.com - October 3 at 1:27 AM
MarketBeat logoSpectrum Pharmaceuticals (NASDAQ:SPPI) Rating Reiterated by JMP Securities
americanbankingnews.com - September 26 at 3:22 AM
benzinga.com logoSpectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) Investor Alert: Kaplan Fox Investigates Potential Securities Fraud
benzinga.com - September 23 at 5:08 PM
finance.yahoo.com logoDespite Regulatory Setback, Spectrum Still "Unique Investment Opportunity," Says Analyst
finance.yahoo.com - September 23 at 5:08 PM
finance.yahoo.com logoSpectrum Pharmaceuticals Provides Update on Poziotinib Following FDA Oncologic Drugs Advisory Committee Meeting
finance.yahoo.com - September 23 at 12:07 PM
marketwatch.com logoSpectrum Pharmaceuticals Shares Slide Premarket After Financing, FDA AdCom
marketwatch.com - September 23 at 12:07 PM
finance.yahoo.com logoSpectrum's stock is down after FDA committee voted against cancer drug
finance.yahoo.com - September 23 at 12:07 PM
benzinga.com logoFDA's Adcomm Gives Thumbs Down To Spectrum Pharmaceuticals' Lung Cancer Candidate
benzinga.com - September 23 at 7:26 AM
reuters.com logoU.S. FDA panel votes against Spectrum's lung cancer drug
reuters.com - September 22 at 1:50 PM
finance.yahoo.com logoWith Upcoming Contentious Meeting, This Analyst Cuts Price Target On Spectrum Pharma
finance.yahoo.com - September 21 at 5:46 PM
seekingalpha.com logoSpectrum to face contentious AdCom meeting over cancer drug – H.C. Wainwright
seekingalpha.com - September 21 at 12:42 PM
reuters.com logoU.S. FDA staff raises concerns on Spectrum Pharma's cancer drug
reuters.com - September 20 at 3:28 PM
finance.yahoo.com logoUPDATE 1-U.S. FDA staff raises concerns on Spectrum Pharma's cancer drug
finance.yahoo.com - September 20 at 3:28 PM
finance.yahoo.com logoFDA advisory committee to review three cancer drugs this week
finance.yahoo.com - September 19 at 4:15 PM
msn.com logoLooking Into Spectrum Pharmaceuticals's Recent Short Interest
msn.com - September 13 at 1:18 PM
finance.yahoo.com logoSpectrum Pharmaceuticals (SPPI) Gets Nod for Rolvedon Injection
finance.yahoo.com - September 12 at 5:10 PM
marketwatch.com logoSpectrum Pharmaceuticals' Rolvedon Injection Approved by FDA
marketwatch.com - September 10 at 7:14 PM
finance.yahoo.com logoSpectrum Pharmaceuticals Announces Data from Poster Presentation for Poziotinib in NSCLC Patients with G778_P780dup HER2 Exon 20 Mutations at ESMO Congress 2022
finance.yahoo.com - September 10 at 9:22 AM
msn.com logoSpectrum Gets FDA Nod For Febrile Neutropenia Candidate, Sees Commercial Launch In Q4 2022
msn.com - September 9 at 6:20 PM
finance.yahoo.com logoSpectrum Pharmaceuticals Receives FDA Approval for ROLVEDON™ (eflapegrastim-xnst) Injection
finance.yahoo.com - September 9 at 6:20 PM
finance.yahoo.com logoSpectrum Pharmaceuticals Announces Poster Presentation for Poziotinib in NSCLC Patients with G778_P780dup HER2 Exon 20 Mutations at the Upcoming ESMO Congress 2022
finance.yahoo.com - September 5 at 8:57 AM
seekingalpha.com logoSpectrum Pharmaceuticals, Inc. (SPPI) CEO Thomas Riga on Q2 2022 Results - Earnings Call Transcript
seekingalpha.com - August 11 at 4:26 PM
finance.yahoo.com logoSpectrum Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
finance.yahoo.com - August 11 at 4:26 PM
finance.yahoo.com logoSpectrum Pharmaceuticals to Report Second Quarter 2022 Financial Results and Provide Corporate Update
finance.yahoo.com - July 29 at 7:59 AM
finance.yahoo.com logoWe're A Little Worried About Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Rate
finance.yahoo.com - June 13 at 5:06 PM
finance.yahoo.com logoSpectrum Pharmaceuticals, Inc. (NASDAQ:SPPI): Is Breakeven Near?
finance.yahoo.com - May 14 at 9:56 AM
seekingalpha.com logoSpectrum Pharmaceuticals, Inc. (SPPI) CEO Thomas Riga on Q1 2022 Results - Earnings Call Transcript
seekingalpha.com - May 12 at 10:32 PM
finance.yahoo.com logoSpectrum Pharmaceuticals to Report First Quarter 2022 Financial Results and Provide Corporate Update
finance.yahoo.com - May 6 at 7:13 AM
finance.yahoo.com logoSpectrum Pharmaceuticals Appoints Brittany K. Bradrick to Board of Directors
finance.yahoo.com - May 5 at 8:00 AM
finance.yahoo.com logoSpectrum Pharmaceuticals Announces FDA Acceptance of BLA Resubmission for Eflapegrastim
finance.yahoo.com - April 11 at 8:39 AM
finance.yahoo.com logoSpectrum Pharmaceuticals Announces Poster Presentation at the Upcoming AACR Annual Meeting
finance.yahoo.com - April 4 at 7:16 AM
finanznachrichten.de logoSpectrum Pharmaceuticals, Inc.: Spectrum Pharmaceuticals Announces an Oral Poziotinib Presentation at the Upcoming ESMO TAT 2022 Virtual Meeting
finanznachrichten.de - April 1 at 9:34 PM
finance.yahoo.com logoSpectrum Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update
finance.yahoo.com - March 11 at 7:35 AM
finance.yahoo.com logoSpectrum Pharma Highlights Poziotinib Data In Treatment-Naïve Lung Cancer Setting
finance.yahoo.com - March 7 at 2:20 PM
finance.yahoo.com logoSpectrum Pharmaceuticals Presents Positive Data for Poziotinib in First-line NSCLC Patients with HER2 Exon 20 Insertion Mutations
finance.yahoo.com - March 7 at 8:54 AM
finance.yahoo.com logoSpectrum Pharmaceuticals Announces an Oral Poziotinib Presentation at the Upcoming ESMO TAT 2022 Virtual Meeting
finance.yahoo.com - February 28 at 7:47 AM
seekingalpha.com logoSpectrum rises 7% as FDA decides to review poziotinib for lung cancer subtype
seekingalpha.com - February 11 at 7:45 AM
finance.yahoo.com logoSpectrum Pharmaceuticals Announces Acceptance of New Drug Application Filing for Poziotinib
finance.yahoo.com - February 11 at 7:45 AM
finance.yahoo.com logoDown 55.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Spectrum Pharma (SPPI)
finance.yahoo.com - February 1 at 2:32 PM
morningstar.com logoGap to leave S&P 500 next week, moving to midcap index
morningstar.com - January 26 at 7:41 PM
marketwatch.com logoSpectrum Pharma to Exit S&P SmallCap 600, Shares Down 5% After Hours
marketwatch.com - January 26 at 7:41 PM
finance.yahoo.com logoSpectrum Pharmaceuticals to Participate in B. Riley Securities 2022 Virtual Oncology Conference
finance.yahoo.com - January 20 at 8:05 AM
nasdaq.com logoSpectrum Pharmaceuticals, Inc. Shares Near 52-Week Low - Market Mover
nasdaq.com - January 8 at 8:52 PM
nasdaq.com logoSpectrum Pharmaceuticals, Inc. Shares Fall 0.8% Below Previous 52-Week Low - Market Mover
nasdaq.com - January 7 at 3:27 AM
nasdaq.com logoSpectrum Pharma To Restructure Organization; To Cut Workforce By Approx. 30%
nasdaq.com - January 5 at 9:24 AM
finance.yahoo.com logoSpectrum Pharmaceuticals Announces Strategic Restructuring
finance.yahoo.com - January 5 at 9:24 AM
finance.yahoo.com logoDid You Acquire (SPPI) Before December 27, 2018? Should Spectrum Pharmaceuticals Management be Held Accountable for Investors Losses? Contact Johnson Fistel
finance.yahoo.com - December 15 at 9:14 AM
finance.yahoo.com logoDown 38% in 4 Weeks, Here's Why You Should You Buy the Dip in Spectrum Pharma (SPPI)
finance.yahoo.com - December 6 at 1:57 PM
finance.yahoo.com logoSpectrum Pharmaceuticals Submits New Drug Application for Poziotinib
finance.yahoo.com - December 6 at 8:31 AM
nasdaq.com logoSpectrum Pharmaceuticals, Inc. Shares Fall 2.6% Below Previous 52-Week Low - Market Mover
nasdaq.com - November 30 at 1:50 PM
Get Spectrum Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SPPI and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:SPPI) was last updated on 10/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.